<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Paris_Bettencourt_Biocompatibility_Testing skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Paris Bettencourt/Biocompatibility Testing</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="col-md-8"><UL class=" text-left wtf-menu "><LI class="parent main-item"><A href="#">Project  </A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Human_Practices">Human Practices</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Applied_Design">Applied Design</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Design">Design</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Production">Production</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Active_Testing">Testing </A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Active_Testing">Active Testing</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Biocompatibility_Testing">Biocompatibility Testing</A></LI></UL><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Model">Modeling</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Optimization">Optimization</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Public_Engagement">Public Engagement</A></LI><LI class="parent main-item"><A href="https://2018.igem.org/Team:Paris_Bettencourt/Software">Software  </A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/AMPDesigner_Overview">AMP Designer Overview</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/AMP_Forest">AMP Forest</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/AMP_Evolver">AMP Evolver</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Result">Result</A></LI><LI class="parent main-item"><A href="#">Judging </A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Medal_Criteria">Medal Criteria </A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Results">Key Results</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/BioBricks">BioBricks</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/InterLab">InterLab</A></LI><LI class="parent main-item"><A href="#">Team  </A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Members">Members</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Collaborations">Collaborations</A></LI><LI><A href="https://2018.igem.org/Team:Paris_Bettencourt/Attributions">Attributions</A></LI><LI class="parent main-item"><A href="https://2018.igem.org/Team:Paris_Bettencourt/Lab_Notebook">Lab Notebook</A></LI><LI class="parent main-item"><A href="https://2018.igem.org/Team:Paris_Bettencourt/Acknowledgements">Acknowledgements</A></LI><DIV id="logolist2"><DIV class="sidelogos top5"><DIV id="twitapp"><A class="twitter-timeline" width="250" height="400" data-dnt="true" href="https://twitter.com/iGEM_Paris" data-widget-id="368144501119795201">@iGEM_Paris</A></DIV></DIV></DIV></DIV><DIV class="textbody h1"><H1>Biocompatibility Testing</H1></DIV><DIV class="textbody"><P> Majority of antimicrobial peptides are cationic, known to interact with and destabilize the negatively charged bacterial membrane via forming pores or transmembrane channels . This leads to cellular stress, loss of membrane potential and ultimately cell death. However these antimicrobial peptides can also interact and form pores in mammalian cells as their membranes are also negatively charged, thus leading to cytotoxicity. Therefore it becomes necessary to evaluate the membrane activity of antimicrobial peptides on mammalian cells.</P><P>Vesicle-encapsulated fluorescent dyes and quenchers (in our case: calcein and cobalt respectively) that change fluorescence on release are commonly used for studying the permeabilization of membranes by peptides or proteins. Leakage of these fluorescent dyes can be measured and could lend an insight on the mechanisms of permeabilization allowing us to confirm the efficiency of these antimicrobial peptides.</P></DIV><DIV class="textbody span"><B>Figure 2:</B>Star core induced vesicle leakage leads to release of fluorescent dye.
</DIV><DIV class="textbody"><P>As demonstrated in 1995 by Ladokhin et al, Vesicle-encapsulated Calcein leakage allows us to confirm that Star-cores exhibit a membrane specific action. Moreover, we can test for selectivity and biocompatibility by studying the permeabilization of vesicles representing bacterial and mammalian membranes respectively. </P></DIV><DIV class="textbody h1"><H1>Results</H1></DIV><DIV class="textbody h2"><H2>Construct: Ferritin-Ovispirin (BBa_K2738006) </H2></DIV><DIV class="textbody span"><B>Figure 1:</B>Mammalian liposome leakage induced by ferritin-ovispirin StarCore <B>(A)</B> and the kinetics of liposome leakage. <B>(B)</B> Ovispirin (5 uM) and ferritin-ovispirin (3 uM) are used at their MIC concentration obtained from previous results.
</DIV><DIV class="textbody"><P> Ovispirin alone lyses the liposome indicating damage to mammalian cell membrane. Ferritin-ovispirin has a reduced effect on the liposome leakage indicating an improvement in biocompatibility towards mammalian cell membrane. The Starcore ferritin-ovispirin has a safer profile in terms of membrane activity as compared to ovispirin alone at their respective MIC concentration.</P></DIV><DIV class="textbody h2"><H2>Construct: Lyase cage-Enterocin (Bba_K2738104)</H2></DIV><DIV class="textbody span"><B>Figure 2:</B>Mammalian liposome leakage induced by lyase cage-Enterocin A StarCore <B>(A)</B> and the kinetics of liposome leakage.<B>(B)</B> Ovispirin (5 uM) and lyase-ovispirin     (3.9 uM) are used at their MIC concentration obtained from previous results.
</DIV><DIV class="textbody"><P>Ovispirin alone lyses the liposome indicating damage to mammalian cell membrane. Lyase-cage-enterocin has a reduced effect on the liposome leakage indicating an improvement in biocompatibility towards mammalian cell membrane. The Starcore ferritin-ovispirin has a safer profile in terms of membrane activity as compared to ovispirin alone at their respective MIC concentration.</P></DIV><DIV class="textbody h1"><H1>Conclusions</H1></DIV><DIV class="textbody"><P>Fusing antimicrobial peptides to scaffold proteins not only improves their antibacterial activity but also confers biocompatibility and makes them less effective on mammalian cell membranes. Our results are supported by previous findings from Lam et al. 2016, where they demonstrated that structurally designed antimicrobials are biocompatible while simultaneously exhibiting good antibacterial activity. </P></DIV><DIV id="footerdiv"><DIV id="mfooter"><DIV class="footbox"><B>Centre for Research and Interdisciplinarity (CRI)</B>
    Faculty of Medicine Cochin Port-Royal, South wing, 2nd floor
    Paris Descartes University
    24, rue du Faubourg Saint Jacques
    75014 Paris, France<A href="mailto:paris-bettencourt-2018@cri-paris.org">paris-bettencourt-2018@cri-paris.org</A></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>